Progress and prospects of gene therapy clinical trials for the muscular dystrophies

被引:51
作者
Bengtsson, Niclas E. [1 ]
Seto, Jane T. [1 ]
Hall, John K. [1 ]
Chamberlain, Jeffrey S. [1 ,2 ]
Odom, Guy L. [1 ]
机构
[1] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA
[2] Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA
关键词
ADENOASSOCIATED VIRUS VECTORS; MODIFIED T-CELLS; SKELETAL-MUSCLE; CANINE MODEL; INTRAVENOUS-INJECTION; REGIONAL DELIVERY; IMMUNE-RESPONSES; ADOPTIVE THERAPY; MOUSE MODEL; EXPRESSION;
D O I
10.1093/hmg/ddv420
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Clinical trials represent a critical avenue for new treatment development, where early phases (I, I/II) are designed to test safety and effectiveness of new therapeutics or diagnostic indicators. A number of recent advances have spurred renewed optimism toward initiating clinical trials and developing refined therapies for the muscular dystrophies (MD's) and other myogenic disorders. MD's encompass a heterogeneous group of degenerative disorders often characterized by progressive muscle weakness and fragility. Many of these diseases result from mutations in genes encoding proteins of the dystrophin-glycoprotein complex (DGC). The most common and severe form among children is Duchenne muscular dystrophy, caused by mutations in the dystrophin gene, with an average life expectancy around 25 years of age. Another group of MD's referred to as the limb-girdle muscular dystrophies (LGMDs) can affect boys or girls, with different types caused by mutations in different genes. Mutation of the alpha-sarcoglycan gene, also a DGC component, causes LGMD2D and represents the most common form of LGMD. Early preclinical and clinical trial findings support the feasibility of gene therapy via recombinant adeno-associated viral vectors as a viable treatment approach for many MDs. In this mini-review, we present an overview of recent progress in clinical gene therapy trials of the MD's and touch upon promising preclinical advances.
引用
收藏
页码:R9 / R17
页数:9
相关论文
共 86 条
[1]   Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity [J].
Adusumilli, Prasad S. ;
Cherkassky, Leonid ;
Villena-Vargas, Jonathan ;
Colovos, Christos ;
Servais, Elliot ;
Plotkin, Jason ;
Jones, David R. ;
Sadelain, Michel .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (261)
[2]   Gene therapy deserves a fresh chance [J].
不详 .
NATURE, 2009, 461 (7268) :1173-1173
[3]   The Polyproline Site in Hinge 2 Influences the Functional Capacity of Truncated Dystrophins [J].
Banks, Glen B. ;
Judge, Luke M. ;
Allen, James M. ;
Chamberlain, Jeffrey S. .
PLOS GENETICS, 2010, 6 (05) :12
[4]   MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy [J].
Barbash, I. M. ;
Cecchini, S. ;
Faranesh, A. Z. ;
Virag, T. ;
Li, L. ;
Yang, Y. ;
Hoyt, R. F. ;
Kornegay, J. N. ;
Bogan, J. R. ;
Garcia, L. ;
Lederman, R. J. ;
Kotin, R. M. .
GENE THERAPY, 2013, 20 (03) :274-282
[5]   Translating the therapeutic potential of neurotrophic factors to clinical 'proof of concept': A personal saga achieving a career-long quest [J].
Bartus, Raymond T. .
NEUROBIOLOGY OF DISEASE, 2012, 48 (02) :153-178
[6]   Long-term Restoration of Cardiac Dystrophin Expression in Golden Retriever Muscular Dystrophy Following rAAV6-mediated Exon Skipping [J].
Bish, Lawrence T. ;
Sleeper, Meg M. ;
Forbes, Sean C. ;
Wang, Bingjing ;
Reynolds, Caryn ;
Singletary, Gretchen E. ;
Trafny, Dennis ;
Morine, Kevin J. ;
Sanmiguel, Julio ;
Cecchini, Sylvain ;
Virag, Tamas ;
Vulin, Adeline ;
Beley, Cyriaque ;
Bogan, Janet ;
Wilson, James M. ;
Vandenborne, Krista ;
Kornegay, Joe N. ;
Walter, Glenn A. ;
Kotin, Robert M. ;
Garcia, Luis ;
Sweeney, H. Lee .
MOLECULAR THERAPY, 2012, 20 (03) :580-589
[7]   A Comprehensive Review of Retinal Gene Therapy [J].
Boye, Shannon E. ;
Boye, Sanford L. ;
Lewin, Alfred S. ;
Hauswirth, William W. .
MOLECULAR THERAPY, 2013, 21 (03) :509-519
[8]   Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome [J].
Boztug, Kaan ;
Schmidt, Manfred ;
Schwarzer, Adrian ;
Banerjee, Pinaki P. ;
Diez, Ines Avedillo ;
Dewey, Ricardo A. ;
Boehm, Marie ;
Nowrouzi, Ali ;
Ball, Claudia R. ;
Glimm, Hanno ;
Naundorf, Sonja ;
Kuehlcke, Klaus ;
Blasczyk, Rainer ;
Kondratenko, Irina ;
Marodi, Laszlo ;
Orange, Jordan S. ;
von Kalle, Christof ;
Klein, Christoph .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20) :1918-1927
[9]   Vascular endothelial growth factor as a biomarker for endostatin gene therapy [J].
Braga, Marina Souza ;
Turaca, Thiago Lauro ;
Foguer, Karen ;
Barbosa Chaves, Karen Cristina ;
Pesquero, Joao Bosco ;
Chammas, Roger ;
Schor, Nestor ;
Bellini, Maria Helena .
BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (06) :511-515
[10]   CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia [J].
Brentjens, Renier J. ;
Davila, Marco L. ;
Riviere, Isabelle ;
Park, Jae ;
Wang, Xiuyan ;
Cowell, Lindsay G. ;
Bartido, Shirley ;
Stefanski, Jolanta ;
Taylor, Clare ;
Olszewska, Malgorzata ;
Borquez-Ojeda, Oriana ;
Qu, Jinrong ;
Wasielewska, Teresa ;
He, Qing ;
Bernal, Yvette ;
Rijo, Ivelise V. ;
Hedvat, Cyrus ;
Kobos, Rachel ;
Curran, Kevin ;
Steinherz, Peter ;
Jurcic, Joseph ;
Rosenblat, Todd ;
Maslak, Peter ;
Frattini, Mark ;
Sadelain, Michel .
SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (177)